PMV Pharmaceuticals, Inc. (PMVP): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de l'oncologie de précision, PMV Pharmaceuticals apparaît comme un innovateur révolutionnaire ciblant l'insaisissable paysage de mutation p53. En tirant parti de la conception avancée de médicaments informatiques et d'une plate-forme technologique propriétaire, cette entreprise de biotechnologie révolutionne le traitement du cancer grâce à des stratégies thérapeutiques hautement ciblées. Leur approche unique promet de débloquer des thérapies potentielles pour des cancers auparavant non traitables, de positionner les produits pharmaceutiques PMV à l'avant-garde de la médecine personnalisée et d'offrir de l'espoir aux patients avec des mutations génétiques complexes qui ont longtemps remis en question les interventions oncologiques traditionnelles.

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: partenariats clés

Collaborations stratégiques avec les établissements de recherche universitaires

PMV Pharmaceuticals a établi des partenariats de recherche critiques avec les établissements universitaires suivants:

Institution	Focus de la collaboration	Année initiée
Université de Pennsylvanie	Recherche de mutation p53	2019
Université Johns Hopkins	Études de précision en oncologie	2020

Partenariats de développement pharmaceutique avec des organisations de recherche contractuelle

PMV Pharmaceuticals collabore avec des organisations de recherche sous contrat spécialisées (CRO) pour le développement de médicaments:

• IQVIA - Gestion des essais cliniques
• Parexel International - Support de recherche préclinique
• MEDPACE - Conception d'essai cliniques en oncologie

Accords de licence potentiels

Les partenariats potentiels de licence pharmaceutique comprennent:

Entreprise pharmaceutique	Zone de collaboration potentielle	Statut
Miserrer & Co.	P53 Thérapies ciblées	Discussions exploratoires
Bristol Myers Squibb	Traitements d'oncologie de précision	Négociations préliminaires

Collaborations de recherche en oncologie de précision

Partenariats de recherche en oncologie en oncologie actuels:

• Memorial Sloan Kettering Cancer Center - Profil moléculaire
• Dana-Farber Cancer Institute - Développement de la thérapie ciblée
• MD Anderson Cancer Center - Recherche génomique

Investissement total de partenariat de recherche: 12,4 millions de dollars en 2023

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: Activités clés

P53 Recherche et développement de médicaments contre le cancer ciblé

Au quatrième trimestre 2023, PMV Pharmaceuticals s'est concentré sur le développement de thérapies ciblées P53 avec un budget de recherche spécifique de 54,3 millions de dollars dédié à la recherche et au développement en oncologie.

Focus de recherche	Investissement	Indication cible
thérapies spécifiques à la mutation p53	28,7 millions de dollars	Tumeurs solides avancées
Nouvelles plateformes d'oncologie de précision	25,6 millions de dollars	Traitements du cancer ciblé

Modélisation moléculaire et conception de médicaments informatiques

PMV utilise des plateformes de calcul avancées avec un investissement technologique annuel de 12,5 millions de dollars dans l'infrastructure de modélisation moléculaire.

• Algorithmes avancés d'apprentissage automatique pour la modélisation d'interaction des protéines
• Systèmes informatiques hautes performances
• Outils de calcul de la biologie structurelle propriétaire

Gestion et exécution des essais cliniques

Budget de développement clinique pour 2024: 67,2 millions de dollars, soutenant plusieurs essais cliniques en cours à travers différentes indications d'oncologie.

Étape clinique	Nombre d'essais actifs	Cible d'inscription des patients
Phase 1	3 essais	180 patients
Phase 2	2 essais	250 patients

Processus de soumission et de conformité réglementaires

Budget des affaires réglementaires: 8,3 millions de dollars, avec une équipe dédiée de 12 spécialistes réglementaires gérant les interactions FDA et EMA.

Développement thérapeutique innovant en oncologie

Investissement en R&D dans les plateformes d'oncologie de précision: 41,9 millions de dollars, ciblant des mutations génétiques spécifiques dans les traitements contre le cancer.

• Approche thérapeutique personnalisée
• Conception de médicaments spécifiques à la mutation
• Stratégies de traitement axées sur les biomarqueurs

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: Ressources clés

Plateforme de technologie de ciblage de mutation P53 propriétaire

PMV Pharmaceuticals a développé une plate-forme technologique spécialisée axée sur le ciblage des mutations de cancer P53 spécifiques. Depuis le quatrième trimestre 2023, la société a identifié et caractérisé plus de 30 cibles de mutation P53 uniques pour des interventions thérapeutiques potentielles.

Métriques de la plate-forme technologique	Données quantitatives
Cibles de mutation p53 uniques	30+ mutations identifiées
Investissement en recherche	12,5 millions de dollars alloués en 2023
Demandes de brevet	8 dépôts de brevet actifs

Équipe de recherche scientifique spécialisée

La société maintient une équipe scientifique robuste avec une profonde expertise en oncologie.

• Personnel de recherche total: 65 employés
• Chercheurs de doctorat: 42
• Domaines de spécialisation: oncologie, biologie informatique, génétique moléculaire

Infrastructure avancée de découverte de médicaments informatiques

Capacités de calcul: PMV utilise des systèmes informatiques à haute performance pour la modélisation moléculaire et la découverte de médicaments.

Composant d'infrastructure	Spécification
Puissance de traitement informatique	512 Teraflops
Capacité de stockage de données	2,5 pétaoctets
Algorithmes d'apprentissage automatique	17 algorithmes développés sur mesure

Portefeuille de propriété intellectuelle

PMV Pharmaceuticals maintient une solide stratégie de propriété intellectuelle pour de nouvelles thérapies contre le cancer.

• Brevets actifs totaux: 12
• Familles de brevets: 5
• Couverture géographique: États-Unis, Europe, Japon

Financement de la recherche et du développement

Les sources de financement soutiennent les initiatives de recherche et développement en cours.

Source de financement	Montant (2023)
Investissements en capital-risque	45,3 millions de dollars
Subventions gouvernementales	7,2 millions de dollars
Collaborations de recherche	3,5 millions de dollars

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: propositions de valeur

Précision Oncology Therapeutics ciblant des mutations P53 spécifiques

PMV Pharmaceuticals se concentre sur le développement de thérapies ciblées contre le cancer abordant spécifiquement les mutations du gène p53. Au quatrième trimestre 2023, la société comptait 3 principaux candidats médicamenteux en développement clinique ciblant des mutations P53 spécifiques.

Drogue	Type de mutation	Étape clinique	Cibler les types de cancer
PC14586	mutation p53 y220c	Phase 1/2	Tumeurs solides
PC577	Mutation p53 R273	Préclinique	Plusieurs types de cancer

Approche innovante du traitement du cancer

L'approche de la médecine de précision de PMV cible des altérations moléculaires spécifiques des cellules cancéreuses. L'évaluation du marché de la société en janvier 2024 était d'environ 425 millions de dollars.

Potentiel pour développer des thérapies pour les cancers auparavant non traitables

• Population de patients adressable estimée pour les mutations P53: environ 50 000 patients par an
• Taille potentielle du marché pour les thérapies de précision P53: plus de 1,2 milliard de dollars
• Ciblage unique des mutations p53 précédemment «non« non prononcées »

Méthodologie avancée de conception de médicaments informatiques

PMV utilise des plateformes de calcul propriétaires pour la découverte de médicaments. Les frais de recherche et de développement en 2023 étaient de 86,3 millions de dollars, ce qui représente une augmentation de 22% par rapport à 2022.

Thérapies ciblées avec un potentiel d'amélioration des résultats des patients

Métrique	Valeur
Investissement en R&D	86,3 millions de dollars (2023)
Investissements d'essais cliniques	42,7 millions de dollars (2023)
Portefeuille de brevets	23 brevets accordés

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de recherche en oncologie

PMV Pharmaceuticals maintient l'engagement direct grâce à des interactions ciblées avec les principaux chercheurs et institutions en oncologie. Depuis le quatrième trimestre 2023, la société a signalé 87 collaborations de recherche directes avec des centres de recherche universitaire et médicale.

Type d'engagement	Nombre d'interactions
Partenariats de recherche universitaire	42
Collaborations du centre médical	35
Réseau de recherche pharmaceutique	10

Conférence scientifique et participation du symposium médical

En 2023, PMV Pharmaceuticals a participé à 17 conférences d'oncologie majeures, présentant des résultats de recherche et s'engager avec des membres de la communauté scientifique.

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Congrès de la Société européenne pour l'oncologie médicale (ESMO)
• Symposium du cancer du sein de San Antonio

Communication transparente des progrès des essais cliniques

La société maintient la transparence grâce à des mises à jour régulières sur les développements des essais cliniques. En 2023, PMV a publié 6 rapports de progression des essais cliniques complets.

Mécanisme de rapport	Fréquence
Présentations des investisseurs	Trimestriel
Bases de données publiques d'essais cliniques	Semestriel
Communiqués de presse	Au besoin

Collaborations du groupe de défense des patients

PMV Pharmaceuticals collabore activement 12 organisations de défense des patients axé sur l'oncologie de précision et les thérapies ciblées.

• National Cancer Survivors Network
• Coalition de plaidoyer en médecine de précision
• Fondation de recherche sur le cancer génétique

Publication scientifique en cours et partage de recherche

En 2023, la société a publié 14 articles scientifiques évalués par des pairs Dans des revues en oncologie et en médecine moléculaire.

Catégorie de publication	Nombre de publications
Journaux évalués par des pairs	14
Résumé de la conférence	22
Présentations de recherche	9

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: canaux

Communication scientifique directe à travers des publications de recherche

PMV Pharmaceuticals publie des recherches dans des revues scientifiques évaluées par des pairs pour communiquer les résultats de la recherche.

Plate-forme de publication	Nombre de publications (2023)
Biotechnologie de la nature	2 publications
Découverte de cancer	3 publications
Thérapeutique du cancer moléculaire	1 publication

Relations des investisseurs et présentations de la conférence financière

L'entreprise utilise des conférences financières pour la communication des investisseurs.

Type de conférence	Nombre de présentations (2023)
Conférence JP Morgan Healthcare	1 présentation
Conférence Cowen Healthcare	1 présentation
Conférence Guggenheim Healthcare	1 présentation

Conférences de la biotechnologie et de l'industrie pharmaceutique

PMV Pharmaceuticals s'engage dans des conférences spécifiques à l'industrie.

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Congrès de la Société européenne pour l'oncologie médicale (ESMO)
• Réunion annuelle de la Society for Immunotherapy of Cancer (SITC)

Plateformes de communication numérique

Canaux numériques pour la communication d'entreprise et la diffusion de l'information.

Plate-forme numérique	Métriques d'engagement (2023)
Site Web de l'entreprise	45 000 visiteurs uniques
Liendin	12 500 abonnés
Gazouillement	8 200 abonnés

Interactions d'agence de réglementation

Canaux de communication formels avec des organismes de réglementation.

• Discussions de réunion de type B de la FDA
• Interactions de conseils scientifiques EMA
• Communications d'application enquête sur les nouveaux médicaments (IND)

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en oncologie

Depuis le quatrième trimestre 2023, PMV Pharmaceuticals possède des partenariats de recherche en collaboration avec 12 grandes institutions de recherche en oncologie.

Type d'institution	Nombre de partenariats	Focus de recherche
Centres de recherche universitaires	7	Recherche de mutation p53
Instituts de recherche sur le cancer	5	Oncologie de précision

Sociétés pharmaceutiques et biotechnologiques

PMV Pharmaceuticals a établi des collaborations stratégiques avec 8 sociétés pharmaceutiques et biotechnologiques.

• Valeur de collaboration totale: 157,5 millions de dollars
• Paiements de jalons potentiels: jusqu'à 1,2 milliard de dollars
• Les accords de licence axés sur les thérapies ciblées p53

Centres de traitement du cancer

Engagement des essais cliniques dans 23 centres de traitement du cancer spécialisés aux États-Unis.

Type de centre	Nombre de centres	Distribution géographique
Centres de cancer complets	12	Couverture nationale
Centres d'oncologie spécialisés	11	Réseaux régionaux

Patients avec des cancers spécifiques de mutation p53

Analyse cible de la population de patients pour les cancers axés sur la mutation p53:

• Population estimée des patients: environ 50 000 patients par an
• Types du cancer primaire: cancers pulmonaires, colorectaux, ovariens et pancréatiques
• Pénétration potentielle du marché: 15 à 20% des segments de patients identifiés

Départements de recherche universitaire

Engagements de recherche collaborative avec les départements universitaires:

Type de département	Nombre de collaborations	Investissement en recherche
Oncologie moléculaire	6	3,2 millions de dollars
Recherche génétique	4	2,7 millions de dollars

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Pour l'exercice 2022, PMV Pharmaceuticals a déclaré des dépenses de R&D de 72,3 millions de dollars, ce qui représente une partie importante de leurs coûts opérationnels.

Exercice fiscal	Dépenses de R&D	Pourcentage des dépenses totales
2022	72,3 millions de dollars	68.4%
2021	63,1 millions de dollars	65.7%

Coûts de gestion des essais cliniques

Les dépenses des essais cliniques pour PMV Pharmaceuticals en 2022 ont totalisé environ 45,2 millions de dollars.

• Essais de phase 1: 18,7 millions de dollars
• Essais de phase 2: 22,5 millions de dollars
• Études précliniques: 4 millions de dollars

Protection et entretien de la propriété intellectuelle

Les coûts annuels de propriété intellectuelle pour PMV Pharmaceuticals étaient d'environ 3,5 millions de dollars en 2022.

Catégorie IP	Coût annuel
Dépôt de brevet	2,1 millions de dollars
Entretien de brevets	1,4 million de dollars

Recrutement et rétention des talents scientifiques

Les dépenses de personnel pour le personnel scientifique en 2022 s'élevaient à 38,6 millions de dollars.

• Salaire moyen du personnel scientifique: 185 000 $
• Personnel scientifique total: 208 employés
• Coûts de recrutement: 1,2 million de dollars

Infrastructure de calcul et de laboratoire avancé

Les investissements en infrastructure et en technologie en 2022 étaient de 15,7 millions de dollars.

Composant d'infrastructure	Investissement annuel
Équipement de laboratoire	9,3 millions de dollars
Systèmes de calcul	6,4 millions de dollars

PMV Pharmaceuticals, Inc. (PMVP) - Modèle d'entreprise: Strots de revenus

Attributions potentielles de licences thérapeutiques potentiels

Au quatrième trimestre 2023, PMV Pharmaceuticals a des accords de licence potentiels avec les paramètres financiers suivants:

Partenaire	Paiement initial potentiel	Potentiel d'étape
Pfizer	25 millions de dollars	Jusqu'à 465 millions de dollars

Subventions de recherche et financement gouvernemental

PMV Pharmaceuticals a reçu le financement de la recherche des sources suivantes en 2023:

• National Institutes of Health (NIH): 2,1 millions de dollars
• Grant du ministère de la Défense: 1,5 million de dollars

Paiements de jalons potentiels provenant de partenariats pharmaceutiques

Structure potentielle de paiement des étapes avec des partenaires pharmaceutiques actuels:

Étape de développement	Montant de paiement d'étape
Achèvement préclinique	10 millions de dollars
Essais cliniques de phase 1	25 millions de dollars
Essais cliniques de phase 2	50 millions de dollars
Approbation de la FDA	100 millions de dollars

Future commercialisation des produits

Potentiel de revenus prévu pour les candidats thérapeutiques principaux:

Produit candidat	Potentiel des revenus annuels estimés
p53 ciblant les thérapies	75 à 120 millions de dollars

Financement des investisseurs et augmentation du capital

Capital Rusinet Détails pour 2023-2024:

• Capital total levé en 2023: 85,4 millions de dollars
• Equivalents en espèces et en espèces au cours du troisième trimestre: 189,3 millions de dollars
• Espèce nette utilisé dans les activités d'exploitation: 67,2 millions de dollars

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Value Propositions

You're looking at the core reasons why PMV Pharmaceuticals, Inc. (PMVP) is positioned to capture value in precision oncology. The value proposition centers on a highly specific, first-in-class molecular intervention for a historically undruggable target.

The primary value is the First-in-class small molecule reactivating the p53 Y220C mutant protein. This molecule, rezatapopt (PC14586), is engineered as a structural corrector. It's designed to selectively bind to the pocket created by the p53 Y220C mutation, which effectively restores the normal, tumor-suppressing function of the p53 protein. This is a novel approach, as TP53 mutations are present in approximately half of all human cancers.

This mechanism supports a Tumor-agnostic therapy for advanced solid tumors with a high unmet need. The therapy targets the underlying mutation rather than the tumor's tissue of origin. Confirmed responses have been observed across eight distinct tumor types, including ovarian, lung, breast, and endometrial carcinoma, in patients whose tumors harbor the TP53 Y220C mutation and are KRAS wild-type. To be fair, there are currently no FDA-approved medicines that specifically target this p53 Y220C mutation, highlighting the significant unmet need. For the lead indication, platinum-resistant/refractory ovarian cancer, PMV Pharmaceuticals estimates the U.S. market opportunity alone is between $350 million and $420 million, based on about 1,700 second-line and later patients in the U.S. and five major European markets.

Clinical activity provides concrete evidence of this value, particularly in the lead indication. PMV Pharmaceuticals has Demonstrated 46% Overall Response Rate (ORR) in ovarian cancer cohort based on updated data. The clinical activity across the basket trial cohorts as of the September 4, 2025 data cutoff date shows compelling, rapid, and durable responses. Here's the quick math on the efficacy data from the Phase 2 pivotal portion:

Efficacy Metric	All Evaluable Patients (n=103)	Ovarian Cancer Cohort (n=44)
Overall Response Rate (ORR)	34%	46% (or 43%)
Median Duration of Response (mDoR)	7.6 months	8.0 months (or 7.6 months)
Median Time to Response	1.3 months	1.3 months

The therapy is also recognized for its potential to address this serious condition rapidly, as evidenced by the FDA Fast Track designation for advanced solid tumors. This designation was granted to rezatapopt for treating patients with locally advanced or metastatic solid tumors carrying the p53 Y220C mutation. This designation is intended to speed up development and review, helping the product reach patients sooner.

The company is actively investing to realize this value, with Research and Development (R&D) expenses at $18.2 million for the quarter ended September 30, 2025. This investment supports the ongoing enrollment, with plans to add an additional 20 to 25 platinum-resistant/refractory ovarian cancer patients by the end of the first quarter of 2026. Financially, PMV Pharmaceuticals ended Q3 2025 with $129.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway to the end of the first quarter of 2027.

The core value propositions can be summarized by what the drug delivers:

• First-in-class p53 Y220C structural corrector.
• Tumor-agnostic approach for advanced solid tumors.
• Observed 46% ORR in the lead ovarian cancer cohort.
• Rapid response time, median of 1.3 months.
• FDA Fast Track designation received.
• Targeting a mutation found in approximately 50% of all cancers.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Customer Relationships

You're looking at how PMV Pharmaceuticals, Inc. manages its key relationships, which for a clinical-stage biotech means heavy focus on investigators, regulators, and the investment community. This isn't about mass-market sales; it's about high-value, targeted engagement.

High-touch engagement with clinical trial investigators and sites is central, given the ongoing development of rezatapopt. The Phase 2 PYNNACLE trial is designed to enroll a total of 114 patients across five cohorts at approximately 60 sites globally. As of October 2024, more than 75% of these sites had been activated across the U.S., Europe, and Asia-Pacific. The engagement is also seen in investigator-initiated studies; for example, one study with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center was planned to enroll approximately 25 patients across two sites starting in Q1 2025. The data readouts themselves become key engagement points; an interim analysis reported in October 2025 included data from 103 evaluable patients, and a September 2025 webinar reviewed data for approximately 65 patients with at least 18 weeks of follow-up.

Metric	Value	Context/Date
Total Planned PYNNACLE Phase 2 Patients	114	PYNNACLE Trial Design
Total Planned PYNNACLE Sites	60	PYNNACLE Trial Design
Activated Sites (as of Oct 2024)	>75%	Of 60 planned sites
Investigator-Initiated Study Sites (AML/MDS)	2	Planned start Q1 2025
Patients in Oct 2025 Interim Analysis	103	Evaluated patients
Patients in Sep 2025 Webinar Analysis	~65	With at least 18 weeks follow-up

The focus on the p53 mutation means PMV Pharmaceuticals, Inc. is engaging with a specific scientific community. The company leverages these interactions to build credibility, for instance, by presenting data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025.

Transparent investor relations through conferences and one-on-one meetings is a consistent activity. Management, including the President and CEO, participated in at least two major investor conferences in the first half of 2025: the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025. Management also committed to one-on-one investor meetings around these events. Furthermore, an investor webinar was held on September 10, 2025, to review Phase 2 interim data. As of Q2 2025, PMV Pharmaceuticals ended the quarter with $148.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway to the end of 2026.

Regulatory dialogue with the US FDA for NDA pathway confirmation is guided by clinical milestones. PMV Pharmaceuticals anticipates submitting a New Drug Application (NDA) by the end of 2026. As of late 2025, the company has not received any FDA approvals for its therapy in the last two years. The data presented in October 2025, showing a 34% overall response rate (ORR) among 103 evaluable patients in the pivotal Phase 2 trial, directly informs this pathway discussion. The trial is designed such that this Phase 2 data will serve as the basis for the NDA, meaning no further Phase 3 studies are planned.

Regarding active participation in patient advocacy groups via the Avoca Consortium, the consortium itself held its 14th year summit in May 2025 (May 13-14, 2025), focusing on clinical trial quality and collaboration. The consortium also released its 2025 Avoca Industry Report on ICH E6(R3) Adoption & Implementation. Specific, verifiable data points confirming PMV Pharmaceuticals, Inc.'s direct membership or level of participation in the Avoca Consortium are not publicly available in the latest reports.

• CEO David H. Mack, Ph.D., and Chief Development Officer Deepika Jalota, Pharm. D., represented PMV Pharmaceuticals at the two listed 2025 investor conferences.
• The Q2 2025 net loss was $21.2 million.
• The Q1 2025 cash position was $165.8 million as of March 31, 2025.

Finance: draft 13-week cash view by Friday.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Channels

You're hiring before product-market fit, so the channels you use to get data and build credibility are everything right now. Here's the quick math on how PMV Pharmaceuticals, Inc. (PMVP) is currently reaching its key audiences, from clinical sites to the scientific community.

Global clinical trial network (PYNNACLE study) for drug delivery

The PYNNACLE Phase 2 monotherapy trial, evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation, is the primary channel for generating core clinical data. The trial was designed to enroll a total of 114 patients across five cohorts at approximately 60 sites globally. As of late 2024, more than 75% of these sites had been activated across the U.S., Europe, and Asia-Pacific. The company planned to submit a New Drug Application (NDA) by the end of 2026. An interim analysis webinar on September 10, 2025, reviewed data for approximately 65 patients with at least 18 weeks of follow-up. Of those patients, approximately 45% were in the ovarian cancer cohort. The company's ability to fund this network was supported by a cash, cash equivalents, and marketable securities balance of $148.3 million as of June 30, 2025, providing an expected cash runway to the end of 2026.

Metric	Value/Status
Total Planned PYNNACLE Phase 2 Patients	114
Approximate Total Trial Sites	60
Activated Sites (Late 2024)	>75%
Expected NDA Filing Date	End of 2026
Q2 2025 Interim Analysis Patients	Approx. 65
Ovarian Cancer Cohort Patients (Q2 2025 Interim)	Approx. 45% of interim group

Future specialty pharmacies and distributors post-regulatory approval

While PMV Pharmaceuticals, Inc. is pre-commercialization, the structure of the specialty drug market informs its future distribution channel strategy. Oncology is a key area of surge in the specialty drug pipeline. Optum Pharmacy Advisory actuaries estimate that per-member-per-month oncology spend will double between 2025 and 2027, ranging from about $8.24 to $15.24. For context on network setup, as of January 2025, 382 unique specialty drugs had a manufacturer-defined limited or exclusive specialty pharmacy network. In those exclusive networks, PBM-affiliated pharmacies had access to only one-quarter of the products.

Direct engagement with key opinion leaders (KOLs) in oncology

Direct engagement channels include scientific presentations where KOLs are often presenters or key attendees. For instance, the oral presentation of the pivotal PYNNACLE Phase 2 initial analysis at the 2025 AACR-NCI-EORTC International Conference on October 24, 2025, was presented by Alison M. Schram, M.D., of Memorial Sloan Kettering Cancer Center. Furthermore, the executive team, including David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, participated in one-on-one investor meetings alongside conference presentations in May and June 2025.

• CEO and CDO participation in one-on-one investor meetings: 2025 (May/June).
• KOL presentation of pivotal trial data at AACR-NCI-EORTC: October 24, 2025.
• Investigator-initiated study support with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center for AML/MDS.

Scientific publications and conference presentations (e.g., AACR-NCI-EORTC)

Scientific dissemination is a critical channel for validating the science behind rezatapopt. PMV Pharmaceuticals, Inc. had two abstracts accepted for presentation at the 2025 AACR-NCI-EORTC International Conference in Boston, MA, held October 22-26, 2025. The company also had a publication in ACS Medicinal Chemistry Letters in 2025, Volume 16, pages 34-39. The company's investor relations activities also function as a channel, with management participating in the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025.

• Publication in ACS Medicinal Chemistry Letters: 2025, Vol. 16, pp. 34-39.
• Oral Presentation at 2025 AACR-NCI-EORTC: Friday, October 24.
• Poster Presentations at 2025 AACR-NCI-EORTC: Friday, October 24 and Saturday, October 25.
• Investor Webinar to review Phase 2 data: September 10, 2025.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Customer Segments

You're looking at the core patient populations PMV Pharmaceuticals, Inc. is targeting with rezatapopt, which is a precision therapy for tumors carrying the TP53 Y220C mutation. The focus is sharp, going after a specific genetic signature across multiple cancer types.

Patients with locally advanced or metastatic solid tumors

The broad initial segment includes patients with advanced disease across various tumor types that share the specific genetic marker. Globally, p53 mutations are found in approximately half of all human cancers.

The current clinical evidence, as of the October 24, 2025 presentation at the AACR-NCI-EORTC International Conference, shows confirmed responses across eight tumor types in the Phase 2 PYNNACLE trial. These types include ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.

The overall efficacy profile for this broad segment, based on the latest data cutoff, shows:

• Overall Response Rate (ORR) of 34% (35/103 evaluable patients).
• Median Duration of Response (DoR) of 7.6 months.
• Median Time to Response of 1.3 months.

Patients specifically harboring the TP53 Y220C mutation

This is the defined target population for rezatapopt. The Y220C mutation itself is found in roughly 1% of all cancers.

For the U.S. market, the total estimated annual patient pool harboring this specific mutation across all solid tumors is approximately 14,000 patients.

Within this segment, the ovarian cancer cohort is a key focus area for PMV Pharmaceuticals, Inc. as they plan their initial New Drug Application (NDA) submission.

Oncologists and specialized cancer treatment centers

Your customer base here isn't just the patient; it's the prescribing physician and the centers capable of administering and monitoring these specialized treatments. These are oncologists treating patients with advanced solid tumors who have undergone or are candidates for genetic testing confirming the TP53 Y220C mutation.

The trial structure itself points to the type of centers engaged. The Phase 2 PYNNACLE study is a registrational, single-arm basket trial, meaning it draws from centers experienced in running complex, multi-tumor trials. The data presented in late 2025 was from a study involving patients who had received prior standard of care treatments.

Platinum-resistant/refractory ovarian cancer patients (initial focus for NDA)

This specific subgroup is the initial regulatory priority. The need is substantial because approximately 80% of patients with advanced ovarian cancer relapse after first-line platinum therapies.

The market for platinum-resistant ovarian cancer in the US, EU4, UK, and Japan was valued at approximately USD 3,012 million in 2025.

PMV Pharmaceuticals, Inc. is targeting this group with a planned NDA submission by the first quarter of 2027. The company plans to enroll an additional 20-25 platinum-resistant/refractory ovarian cancer patients by the end of the first quarter of 2026 to support this submission.

The efficacy in this specific cohort, as of the latest update, is compelling compared to the standard of care, which has less than a 20% response rate in this population:

Tumor Type Cohort	Evaluable Patients	Overall Response Rate (ORR)	Median Duration of Response (DoR)
Ovarian Cancer	48	46% (22/48 patients)	8.0 months
Breast Cancer	12	17% (2/12 patients)	Data not specified
Endometrial Cancer	5	60% (3/5 patients)	Data not specified
Lung Cancer	19	21% (4/19 patients)	Data not specified

Financially, as of September 30, 2025, PMV Pharmaceuticals, Inc. held $129.3 million in cash, cash equivalents, and marketable securities, which provides an expected cash runway to the end of the first quarter of 2027, aligning with the planned NDA submission timeline for this key customer segment.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Cost Structure

You're looking at the cost side of PMV Pharmaceuticals, Inc. (PMVP) as they push their lead candidate through pivotal trials. For a clinical-stage biotech, the burn rate is almost entirely tied to R&D, and the numbers from late 2025 confirm that focus.

The biggest cost driver is definitely Research & Development (R&D) expenses, which hit $18.2 million for the third quarter ended September 30, 2025. That's up from $16.9 million in the same quarter of 2024. Honestly, this jump tells you exactly where the money is going: advancing rezatapopt in the PYNNACLE study.

General and administrative (G&A) expenses were lighter, coming in at $4.3 million for Q3 2025. That's actually a decrease from $4.9 million in Q3 2024, largely because of lower spending on stock-based compensation and general facility costs. It's good to see some operational costs ticking down while the core R&D spend rises.

Here's a quick look at the key operating expenses for the period:

Expense Category	Q3 2025 Amount (in millions USD)	Driver/Context
Research & Development (R&D)	$18.2	Advancement of rezatapopt program
General & Administrative (G&A)	$4.3	Reduced stock-based compensation

The R&D spend is heavily weighted toward external partners. You can expect significant costs here for Contractual Research Organizations (CROs) and the actual running of clinical trials. This is the price of admission for a company in Phase 2 development.

Regarding the clinical and manufacturing spend, the primary visible cost component is the clinical execution. Manufacturing and Chemistry, Manufacturing, and Controls (CMC) costs are inherent but are typically bundled or less detailed than the direct clinical spend in these quarterly releases. What we do know is the clinical activity:

• R&D increase driven by increased contractual research organization costs.
• Advancing the rezatapopt program through the PYNNACLE study.
• The study is a Phase 2 pivotal portion evaluating rezatapopt.
• Observed Overall Response Rate (ORR) of 34% across all cohorts (103 evaluable patients).
• Ovarian cancer cohort showed a 46% ORR among 48 evaluable patients.

The cash position reflects this burn rate; PMV Pharmaceuticals ended the third quarter with $129.3 million in cash, cash equivalents, and marketable securities. Finance: draft 13-week cash view by Friday.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PMV Pharmaceuticals, Inc. as of late 2025. Honestly, for a company at this stage, the revenue streams are almost entirely potential, backed by a solid balance sheet to fund operations until the next big inflection point.

Zero Product Revenue as of Late 2025 (Pre-Commercial Stage)

As of the third quarter ended September 30, 2025, PMV Pharmaceuticals, Inc. is firmly in the pre-commercial development phase. For the quarter, revenue was not reported, and consensus expectations were for $0.00. This means all operational funding currently comes from financing activities and investment income, not product sales.

Potential Future Revenue from Rezatapopt Product Sales Post-NDA Approval

The primary future revenue driver is the commercial sale of rezatapopt, a p53 reactivator. The company is targeting a New Drug Application (NDA) submission for platinum-resistant/refractory ovarian cancer in the first quarter of 2027. This timeline sets the earliest realistic expectation for product revenue generation post-approval, which is contingent on successful regulatory review.

Clinical data supports this future potential:

• Overall Response Rate (ORR) across all cohorts: 34% among 103 evaluable patients.
• ORR specifically in the ovarian cancer cohort: 46% among 48 evaluable patients.
• Median Duration of Response (DOR) in ovarian cancer cohort: 8.0 months.

Potential Upfront and Milestone Payments from a Future Licensing or Collaboration Deal

While PMV Pharmaceuticals, Inc. has not publicly disclosed specific, signed upfront or milestone payment figures as of late 2025, the progress in the Phase 2 pivotal portion of the PYNNACLE study serves as the key value driver for future partnership discussions. The company's current cash position is intended to fund operations through the NDA submission, but positive data strengthens the negotiating position for potential out-licensing deals or collaborations that would bring in non-dilutive capital via upfront payments and future milestone achievements.

Interest Income on Cash and Marketable Securities

This is the only current, tangible financial inflow stream supporting operations outside of financing. PMV Pharmaceuticals, Inc. ended the third quarter of 2025 with $129.3 million in cash, cash equivalents, and marketable securities. This balance provides an expected cash runway to the end of the first quarter of 2027. The company noted that this extended runway reflects both spend pacing and strong interest income. Here's the quick math on the cash position change:

Metric	Value as of September 30, 2025	Value as of June 30, 2025
Cash, Cash Equivalents, and Marketable Securities	$129.3 million	$148.3 million
Net Cash Used in Operations (9 months ended 9/30/2025)	$56.4 million	N/A

What this estimate hides is the exact dollar amount attributed to interest income versus the principal draw-down, but its inclusion in the runway extension narrative confirms it as an active, though secondary, revenue stream.

Finance: draft 13-week cash view by Friday.